Simpson Andrew, Maeda Sadatoshi, Marsella Rosanna
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610-0126, USA.
J Vet Med Sci. 2009 Sep;71(9):1177-81. doi: 10.1292/jvms.71.1177.
The immunopathology behind atopic dermatitis (AD) involves a myriad of inflammatory cells and their mediators. Thymus and activation-regulated chemokine (TARC) plays a significant role in the inflammatory phase by recruiting CCR4(+) T(H)2 cells. In addition, CD25(+) activated T cells further propagate the allergic response after sensitization by producing cytokines. The purpose of this pilot study was to evaluate how exposure to a common allergen (house dust mite, HDM) would affect the proportions of circulating CD4(+)CCR4(+) T(H)2 cells and CD4(+)CD25(+)activated T cells in an experimental model of AD using high-IgE Beagles. In this experimental model, previously sensitized Beagles develop lesions and pruritus upon allergen challenge consisting of 3-day environmental exposure, 3 hours/day. Blood samples were obtained before, during, and after the end of challenge (days 0, 2, 4, and 17). Clinical signs were evaluated and scored at the same time points. Peripheral blood mononuclear cells (PBMCs) were isolated and used for flow cytometry to identify proportions of CD4(+)cells positive for either CCR4 or CD25 receptors. Both CD4(+)cell types (CD25(+) and CCR4(+)) peaked at day 17, when clinical signs had resolved. It is proposed that the increase of circulating CD4(+)CCR4(+) and CD4(+)CD25(+)cells most likely demonstrates the sensitization status of atopic individuals after environmental allergen challenge. Understanding of these two cell types could prompt additional research concerning therapeutic drugs for AD.
特应性皮炎(AD)背后的免疫病理学涉及众多炎症细胞及其介质。胸腺和激活调节趋化因子(TARC)通过募集CCR4(+) T(H)2细胞在炎症阶段发挥重要作用。此外,CD25(+) 活化T细胞在致敏后通过产生细胞因子进一步加剧过敏反应。本初步研究的目的是评估在使用高IgE比格犬的AD实验模型中,暴露于常见过敏原(屋尘螨,HDM)如何影响循环CD4(+)CCR4(+) T(H)2细胞和CD4(+)CD25(+)活化T细胞的比例。在这个实验模型中,先前致敏的比格犬在过敏原激发后会出现病变和瘙痒,激发过程包括每天3小时、持续3天的环境暴露。在激发前、激发期间和激发结束后(第0、2、4和17天)采集血样。在相同时间点评估和记录临床症状。分离外周血单核细胞(PBMC)并用于流式细胞术,以确定CCR4或CD25受体阳性的CD4(+)细胞的比例。两种CD4(+)细胞类型(CD25(+)和CCR4(+))在临床症状消退的第17天达到峰值。有人提出,循环CD4(+)CCR4(+)和CD4(+)CD25(+)细胞的增加很可能表明环境过敏原激发后特应性个体的致敏状态。对这两种细胞类型的了解可能会促使开展更多关于AD治疗药物的研究。